Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Astellas’ Veozah wins regulatory nod as non-hormonal menopause treatment

By Brian Buntz | May 15, 2023

Astellas PharmaTokyo-based Astellas Pharma has won FDA approval for Veozah (fezolinetant) 45 mg to treat moderate to severe vasomotor symptoms associated with menopause. The non-hormonal menopause treatment represents the first neurokinin 3 receptor antagonist to win FDA backing for vasomotor symptoms, which afflict 60-80% of women during menopause.

The approval was based on the BRIGHT SKY program, which included three phase 3 trials enrolling more than 3,000 women. The studies demonstrated Veozah reduced hot flash frequency and severity.

Fezolinetant is a neurokinin 3 (NK3) receptor antagonist. It works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center of the brain—the hypothalamus—to curb the frequency and severity of moderate to severe VMS.

In a statement, Astellas noted that marketing applications are under review in the European Union, Switzerland and Australia. The company has updated its 2024 projections based on the regulatory win.

According to one analyst report, the global menopause treatment market is worth roughly $13.3 billion, and could hit $22.9 billion by 2032.

The menopause treatment landscape has evolved considerably over the years. Initially, hormone replacement therapy (HRT) was the mainstay of treatment for hot flashes and other menopause symptoms. HRT has steadily lost market share, however, due to concerns related to an increased risk of breast cancer, heart disease and stroke.

Consequently, several non-hormonal treatments hit the market. Off-label treatments that have found use include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and gabapentin. Such therapies, however, are generally less effective than HRT and can also have side effects such as nausea, dry mouth and weight gain.

In 2013, the FDA approved Brisdelle, the first non-hormonal treatment specifically for hot flashes. Brisdelle contains paroxetine, a type of SSRI. Paroxetine can also have side effects similar to other SSRIs, such as sleep problems, dry mouth and nausea, and can interact with numerous other medications.

Ultimately, the approval of Veozah could represent a new chapter in the treatment of hot flashes. As the first non-hormonal NK3 receptor antagonist, it offers a new mechanism of action to reduce the frequency and severity of hot flashes. In addition, the safety and efficacy data from the BRIGHT SKY program suggest that Veozah has the potential to improve the quality of life for millions of women.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE